Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Rescue of cone and rod photoreceptor function in a CDHR1-model of age-related retinal degeneration

Yusuf IH. et al, (2024), Molecular Therapy

A Prospective, Observational, Noninterventional Clinical Study of Participants With Choroideremia: The NIGHT Study.

Maclaren RE. et al, (2024), Am J Ophthalmol, 263, 35 - 49

Assessment of Visual Function With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study

Lam BL. et al, (2024), Ophthalmology

Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study.

Casswell EJ. et al, (2024), The British journal of ophthalmology, 108, 440 - 448

CRISPR Manipulation of Age-Related Macular Degeneration Haplotypes in the Complement System: Potential Future Therapeutic Applications/Avenues.

Salman A. et al, (2024), Int J Mol Sci, 25

A hypomorphic variant of choroideremia is associated with a novel intronic mutation that leads to exon skipping.

Waldock WJ. et al, (2024), Ophthalmic Genet, 1 - 8

Comment on Di Giosaffatte et al. A Novel Hypothesis on Choroideremia-Manifesting Female Carriers: Could CHM In-Frame Variants Exert a Dominant Negative Effect? A Case Report. Genes 2022, 13, 1268.

Fry LE. and MacLaren RE., (2023), Genes, 14

Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial

MacLaren RE. et al, (2023), Nature Medicine

Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic RPE65-Mediated Inherited Retinal Dystrophies in a Cohort of Patients from a Single Center

Kiraly P. et al, (2023), Biomolecules, 13, 1484 - 1484

Choroideremia: The Endpoint Endgame.

Abdalla Elsayed MEA. et al, (2023), Int J Mol Sci, 24

Hypomorphic CDHR1 variants may result in retinitis pigmentosa with relative preservation of cone function.

Farag S. et al, (2023), Ophthalmic Genet, 1 - 6

Correlation Between Fundus Autofluorescence Pattern and Retinal Function on Microperimetry in Choroideremia.

Poli FE. et al, (2023), Transl Vis Sci Technol, 12

The Role of Inflammation in Age-Related Macular Degeneration—Therapeutic Landscapes in Geographic Atrophy

Borchert GA. et al, (2023), Cells, 12, 2092 - 2092

Current and Future Landscape in Genetic Therapies for Leber Hereditary Optic Neuropathy.

Shamsnajafabadi H. et al, (2023), Cells, 12

Microperimetry as an Outcome Measure in RPGR-associated Retinitis Pigmentosa Clinical Trials

Taylor LJ. et al, (2023), Translational Vision Science & Technology, 12, 4 - 4

Choroideremia: Toward Regulatory Approval of Retinal Gene Therapy.

Yusuf IH. and MacLaren RE., (2023), Cold Spring Harb Perspect Med, 13

Developmental Expression of the Cell Cycle Regulator p16INK4a in Retinal Glial Cells: A Novel Marker for Immature Ocular Astrocytes?

Martinez-Fernandez de la Camara C. et al, (2023), Journal of Histochemistry & Cytochemistry, 71, 301 - 320

A cross-sectional study to assess the clinical utility of modern visual function assessments in patients with inherited retinal disease: a mixed methods observational study protocol.

Taylor LJ. et al, (2023), BMC Ophthalmol, 23

Programmable RNA editing with endogenous ADAR enzymes – a feasible option for the treatment of inherited retinal disease?

Bellingrath J-S. et al, (2023), Frontiers in Molecular Neuroscience, 16

Microperimetry Reliability Assessed From Fixation Performance

Josan AS. et al, (2023), Translational Vision Science & Technology, 12, 21 - 21

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?